WO1989008261A1 - Composition de detection et/ou de quantification simple de substances antigeniques dans des liquides corporels - Google Patents
Composition de detection et/ou de quantification simple de substances antigeniques dans des liquides corporels Download PDFInfo
- Publication number
- WO1989008261A1 WO1989008261A1 PCT/NO1989/000021 NO8900021W WO8908261A1 WO 1989008261 A1 WO1989008261 A1 WO 1989008261A1 NO 8900021 W NO8900021 W NO 8900021W WO 8908261 A1 WO8908261 A1 WO 8908261A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- erythrocytes
- antibodies
- reactive
- protein
- compositions according
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 42
- 230000000890 antigenic effect Effects 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000001514 detection method Methods 0.000 title claims abstract description 16
- 238000011002 quantification Methods 0.000 title claims abstract description 16
- 239000007788 liquid Substances 0.000 title claims abstract description 14
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 50
- 239000000427 antigen Substances 0.000 claims abstract description 28
- 102000036639 antigens Human genes 0.000 claims abstract description 28
- 108091007433 antigens Proteins 0.000 claims abstract description 28
- 210000004369 blood Anatomy 0.000 claims abstract description 28
- 239000008280 blood Substances 0.000 claims abstract description 28
- 230000002776 aggregation Effects 0.000 claims abstract description 17
- 238000004220 aggregation Methods 0.000 claims abstract description 17
- 239000003446 ligand Substances 0.000 claims abstract description 13
- 210000002381 plasma Anatomy 0.000 claims abstract description 9
- 102100032752 C-reactive protein Human genes 0.000 claims description 42
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 41
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 9
- 229940072221 immunoglobulins Drugs 0.000 claims description 8
- 108010062374 Myoglobin Proteins 0.000 claims description 6
- 102000036675 Myoglobin Human genes 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 210000000601 blood cell Anatomy 0.000 claims description 5
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 claims description 4
- 239000000282 fibrinogen degradation product Substances 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical group C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims description 2
- 101710190759 Serum amyloid A protein Proteins 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical group NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000004879 turbidimetry Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 12
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 22
- 108700028909 Serum Amyloid A Proteins 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 102000004506 Blood Proteins Human genes 0.000 description 7
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 5
- 230000001588 bifunctional effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000208 fibrin degradation product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 4
- 206010048998 Acute phase reaction Diseases 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 3
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004658 acute-phase response Effects 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000004848 nephelometry Methods 0.000 description 2
- SBUYBNIDQXQZSZ-UHFFFAOYSA-N p-aminophenylphosphocholine Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC1=CC=C(N)C=C1 SBUYBNIDQXQZSZ-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000016955 Erythrocyte Anion Exchange Protein 1 Human genes 0.000 description 1
- 108010014384 Erythrocyte Anion Exchange Protein 1 Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000005890 Spectrin Human genes 0.000 description 1
- 108010019965 Spectrin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 241000218220 Ulmaceae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000012092 latex agglutination test Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/586—Liposomes, microcapsules or cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/805—Haemoglobins; Myoglobins
Definitions
- This is invention relates to compositions useful in the detection and quantification of antigenic substances in body liquids.
- Antigenic substances are molecules with structures to which specific antibodies of polyclonal and monoclonal origin can bind.
- General immunological literature describes the formation and production of antibodies and antibody fragments reactive to antigens of different origins.
- fibrin from fibrinogen is a part of the thrombotic process in vivo.
- both thrombosis and fibrinolysis simultaneously take place.
- fibrin degradation products appear in circulating blood as signs of thromboembolic processes in the body, and may be detected and quantified as antigens reactive to antibodies in immunoassays (Devine & al: Blood 68, 317-319, 1986. Elms & al.: Thrombosis & Haemostasis 50, 591-594, 1983. Mirshaj & al.: Thrombosis res. 44, 715-728, 1986.
- the acute phase proteins constitute a group of individual proteins which share, one common characteristics: Their plasma concentrations are altered when an organism, i.e. a patient, undergoes a disease involving inflammation and/or infection. Also neoplastic diseases may induce inflammatory reactions causing acute phase reactions. (Chambers RE & al: "Akute-Phase-Proteine bei entzuriumen preparationen", Diagnose und Labor 36: 124-132, 1986).
- C-reactive protein was first reported in 1930 as a human serum protein that binds to the C-polysaccharide of the pneumococcus cell membrane (Tillet W.S. and Francis T: "Seriological reaction in pneumonia with a non-protein somatic fraction of pneumococcus", J.Exp. Med.52:561-571, 1930). Later it was demonstrated that C- reactive protein binds to phosphoryl choline residues and to aminoethyldihydrogen phosphate residues of this fraction, and these bindings have been utilized for the purification of C-reactive protein and serum. (Volanakais J.E. & al: J. Immunol. Methods 23, 285-295, 1978), (Potent M.
- CRP C-reactive-protein 50 years on; Lancet 1:653-657, 1981).
- the CRP molecule consists of 5 identical subunits held together by non-covalent bonds (Pepys MB: se above).
- Pepys MB se above.
- Several methods for CRP detection and quantification are available, including immunoprecipitation (Andersen HC, and McCarty M: "Determination of C-reactive protein in blood as measure of the activity of the disease process in acute rheumatic fever", Am.J. Med. 8: 445-445, 1950);(Wadsworth C: "A rapid spot immuno-precipitate assay method applied to quantitating C-reactive protein in pediatric sera”. Scand. J. Immunol.
- Serum amyloid A consists of a single polypeptide chain of molecular weight 11 000 - 14 000. This subunit is associated with high density lipoprotein, then to a molecular weight of 85 000 - 200 000 (Anders, RF., Natvig, J., Michalsen TE & Huseby G. Isolation and characterisation of amyloid related SAA as a small molecular weight protein. Scandinavian Journal of Immunology 4, 397-640, 1977). (Rosenthal CJ. et Franklin, EC; "Variation with age and disease of an amyloid A protein related serum component". Journal of Clinical Investigation, 55, 746-753, 1975). The function of SAA is not known, but it behaves as an acute phase reactant.
- SAA seems to be an apolipoprotein of a fraction of high density lipoprotein molecules.
- the LI protein is a highly immunogenic protein of about 36500 daltons that can be purified from granulocytes with good yield. It is present in the cytoplasm of ' virtually all resting peripheral neutrophiles and monocytes.
- CRP, and SAA and LI are presently the plasma proteins known to have the most prominent concentration differences between the normal plasma concentrations and the plasma concentrations in acute inflammatory and infectious phase reactions. Since the increase in blood concentration of CRP, SAA and LI is a very rapid response to infections and tissue damage, their determination are especially valuable in acute medical situations. A large number of acute medical incidents take place in general medical practice far from advanced medical laboratories. Most of the known methods for the detection and/or quantification of increased CRP, SAA and LI concentrations utilize laboratory equipment like spectrophotometers, radioactivity counters, nephelometric equipment, and a time consuming isolation of serum or plasma from whole blood is necessary.
- Antibodies with specific affinity for body liquid antigens are obtained by immuniza ⁇ tion of animals with purified antigens. Monoclonal antibodies reactive to the said antigens may be obtained by fusion of spleen cells from animals immunized with antigen or fragments thereof with suitable cancer cell lines (K ⁇ hler and Milstein. "Continous cultures of fused cells secreting antibodies of predefined specificity", Nature 286, 495-497, 1975). In vivo immunization techniques may also be applied. Several of the immunological techniques utilize modified antibodies, i.e. antibodies conjugated to enzymes or fluorescent moieties or radioactive labels.
- This invention relates to the use of conjugates or hybrids of different antibodies for detection and/or quantification of antigenic substances in samples of body liquids, especially in whole blood samples. Contrary to other methods using signal • forming molecules like enzymes or radioactive or fluoroscent moities or advanced equipment or latex agglutination, the present invention utilizes a constituent of the blood itself to indicate the presence of elevated concentration of the relevant antigenic substances.
- conjugation or hybridization of antibodies or ligands reactive to the relevant antigenic substances with antibodies reactive to ery- throcyte antigens a chemical composition is obtained which is able to aggregate erythrocytes in presence of the relevant antigenic substances.
- two or more identical conjugates or hybrides may bind to the antigenic substance and at the same time bind to the erythrocytes present in the sample or added to the sample if necessary, thus inducing an aggregation of the said erythrocytes.
- the relevant antigenic substances are not constituted by two or more identical subunits, mixtures of different antibody conjugates or hybrids may be used, characterized by at one hand all being reactive to the erythrocytes, present in the sample or if necessary added to the sample, and on the other hand reactive to different epitopes on the relevant antigenic substances.
- CRP consist of five identical subunits, thus several conjugates may bind to the same CRP molecule. In this way the conjugates and CRP build bridges between erythrocytes, forming aggregates of the said erythrocytes. Mixtures of different antibodies binding to different epitopes of e.g. LI, myoglobin, CRP or SAA may be used.
- fibrinogen degradation products When fibrinogen and fibrin are degraded in vivo, fibrinogen degradation products of variable molecular weight are formed.
- Several antigens and epitopes of these degradation products have been investigated, and several of these antigenic determinants and epitopes are not expressed in fibrinogen. Conjugates of antibodies reactive to such determinants and epitopes, with antibodies, reactive to erythrocytes induce aggregation of the erythrocytes in presence of such determinants and epitopes, thus whole blood testing for fibrinogen degradation products is made possible.
- Erythrocytes of a particular species contain numerous different antigenic deter ⁇ minants, several of these antigens being common to all members of the species, and several antigens are common only to a limited number of the members of the species (i.e. blood group antigens) (Van Bennet: "The membrane skeleton of human erythrocytes and its implications for more complex cells", Ann. Rev. Biochem. 1985, 54: 273-304).
- This invention is favourably applied with conjugates or hybrids of antibodies reactive to erythrocyte antigens common to all members of the species.
- Peripheral erythrocyte proteins like spectrin, ankyrin and Band 3 proteins may favourably serve as determinants.
- This invention may also utilize antibodies reactive to all human cells, then all the cellular constituents of the blood will take part in the aggregation reaction.
- Monoclonal or polyclonal antibodies to erythrocyte antigens may be obtained by immunization with erythrocyte antigens. Monoclonal antibodies reactive to all human cells have been produced by the inventor. Conjugates between antibodies or ligands reactive to the relevant antigenic substances and antibodies reactive to erythrocyte antigens or common human cell antigens may be formed by several different methods. A glutaraldehyde activation followed by conjugation is easily performed, but is not optimal from a biochemical functional point of view. Bifunctional linkers such as - but not limited to - bifunctional diimidates, bifunctional dimaleimides, bifunctional maleimido-imides, and other bifunctional . linkers may be used. Also linkages between the carbohydrate moities of immunglobulins or between sulphydryl moities may be formed.
- Immunoglobulins consist of different polypeptides which are held together by disulfide linkages. These disulfide linkages may undergo reductive cleavage and the fragments formed may be separated under acid conditions. By neutralization, such fragments will reunite. If the fragments formed from antibodies reactive to eryth ⁇ rocyte antigens are mixed and then allowed to reunite with fragments formed from antibodies reactive to the relevant antigenic substances, hybrids of antibodies which are reactive both to the relevant antigenic substances and reactive to erythrocytes may be formed.
- the protein conjugates described may be replaced by conjugates between antibodies, reactive to erythrocytes or to all blood cells, and ligands containing phosphorylcholine residues or aminoethyldihydrogen phosphate residues, because _ these ligand residues bind to C-reactive protein in presence of Ca (II).
- Immunological purification of the hybrids or the conjugates may be purified by affinity chromatography.
- conjugates or hybrids When such conjugates or hybrids have been isolated, they may be kept in solution, if necessary with preservatives, or lyophilized, for later use. In the actual clinical situation, these conjugates or hybrids can be combined with whole blood from the patient, most practically with capillary blood obtained by microsampling.
- the solution of conjugates or hybrids, or the redissolved lyophilized dry solid obtained may contain anticoagulants prohibiting coagulation of the blood added. After a short incubation time, aggregation of the erythrocytes is observed if the relevant antigen is present in an appropriate concentration in the blood added. The sensitivity of the aggregation reaction is adjusted by adjustment of the amount of conjugate or hybrid present.
- Aggregation of the blood cells may be observed visually in tubes, on slides from glass or plastics or by other techniques found practical.
- a more precise quantifi ⁇ cation of the relevant antigenic substance present may be obtained by particle counting, i.e. by counting the number of aggregated and/or non- aggregated erythrocytes, turbidimetric quantification, optotermic spectroscopy, thin layer chromatographic separation of aggregates from free non-aggregated erythrocytes, and other measuring techniques.
- Antibodies to different antigenic determinants, epitopes, on relevant antigenic substances and to different antigenic determinants on erythrocytes are available.
- hybrids or conjugates reactive to on one hand erythrocytes and on the other hand different epitopes on the relevant antigenic substance may be formed.
- These type of conjugates or hybrids may be used in combination to streng ⁇ then the aggregation reactions and to increase the sensitivity of the test: In this way more than one single (type of) conjugate or hybrid may serve as linker between the relevant antigenic substance and the erythrocytes, thus facilitating the aggregation reaction.
- compositions comprising mixtures of different conjugates or hybrids may favourably be in the very same buffer solution or in the same lyophylized solid, thus a simple mixing of the claimed composition and the blood from the invidial to be tested may be the only technical handling necessary, optionally followed by instrumental handling for quantitative measurement of the aggregation reaction.
- erythrocytes from any individual may be added to form the necessary aggregates.
- Tests may also, by additon of erythrocytes, be performed on samples of urin or cerebrospinal fluid.
- compositions for detection and/or quantification of antigenic substances present in a sample of body liquid will have a certain measuring range.
- the amount of ligand or immunoglobulin conjugate or hybrid present must be adjusted.
- the sensitivity for antigenic substance detection and/or quantification at the optimized conjugate/hybrid concentration may be adjusted or decreased by addition of antibodies reactive to the relevant antigen, which have not been conjugated or hybridized with antibodies reactive to erythrocytes. These adjustments must be performed according to the actual clinical application, i.e. how much blood should be combined with the composition, and how sensitive to elevated antigenic substance concentrations the test should be.
- Both antibodies of monoclonal and polyclonal origin may be used in the present invention. However, monoclonal antibodies are easier to standardize, conjugate and hybridize and will give higher yields after immunological purification. If available, non-immunoglobulin ligands that bind to the relevant antigenic substance may replace the antibodies. E.g. phosphorylcholine residues or aminoethyldihydrogen phosphate residues may replace anti-CRP-antibodies, since such ligands binds to CRP.
- compositions according to this invention may be formed to aggregate eryth ⁇ rocytes of the human species or of other species in presence of the relevant antigenic substance in a clinically significant concentrations in samples of body liquids.
- Mouse IgG monoclonal antihuman C-reactive antibodies were formed by conventional hybridoma technique and isolated from mouse ascites. Similarly mouse monoclonal IgG reactive to human erythrocyte membranes was produced by conventional hybridoma technique. Both the anti CRP antibodies and the antieryth- rocyte antibodies were dissolved in sodium phosphate buffer at neutral pH. N- succinimidyl 3 - (2-pyridyldithio) propionate (abbreviated SPDP) was dissolved in ethanol to 20 mM concentration. The SPDP solution was added to both immunoglo ⁇ bulins solutions in 3-4 molar excess to the immunoglobulins. The solution was left to react for 30 minutes at 23 °C with occasional stirring.
- SPDP N- succinimidyl 3 - (2-pyridyldithio) propionate
- Monoclonal mouse IgG reactive to all human cells was produced and purified by conventional hybridoma technique from a cell line available in the laboratory.
- P-aminophenylphosphoryl choline acid was conjugated to the antibodies in a one step reaction by means of bis-(sulfosuccinimidyl)-suberate, where the p-aminophenylphosphoryl choline acid was present in 15 molar excess to the antibodies, and bis-(suIfosuccinimidyl)suberat was present In 20 fold molar excess to the antibodies.
- the conjugate was purified by gel chromatography. Immunological purification of conjugates reactive on one hand to C-reactive protein and on the other hand to erythrocytes was performed by affinity chromatography.
- Example 1 Equivalent to Example 1, though antibodies reactive to CRP was replaced by antibodies reactive to myoglobin. 4.
- the conjugate described in Example 1 was demonstrated to have the ability to aggregate the erythrocytes in presence of human C-reactive protein.
- the conjugate described in example 1 required higher concentration of CRP to be present when non- conjugated antibodies reactive to CRP had been added, demonstrating that non- conjugated antibodies reactive to the same epitopes on CRP as the conjugate described in example 1 could be used to reduce the sensitivity of the aggregation reaction.
- a test system could be adjusted to induce aggregation of erythrocytes when a clinically significant concentration of CRP is present.
- Monoclonal antibodies reactive to human fibrin degradation products - but not to fibrinogen - and mouse monoclonal anti-human erythrocyte antibodies were produced by conventional hybridoma technique.
- the anti-erythrocyte monoclonal antibodies and the anti-human fibrin degradation products monoclonal antibodies were conjugated by SPDP as described in example 1.
- the conjugates were isolated, and the conjugates reactive on one hand to the erythrocytes and on the other hand to fibrin degradation products were purified with affinity chromatography techni ⁇ ques.
- erythrocytes were made to aggregate in presence of CRP or myoglobin or fibrin degradation products. The aggregation could be visually observed on transparent slides and in tubes. Further more, it was demonstrated that the aggregation reaction reduced the absorption of light passing through a cuvette where the erythrocytes were suspended. Furthermore, it was demonstrated that, while erythrocytes migrated in chromatography paper, aggregates were withheld to a reduced travelling distance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
On a mis au point des compositions de diagnostic comprenant des conjugués de ligands ou d'anticorps, ou d'hybrides d'anticorps réactifs à la fois à des substances spécifiques (par exemple des antigènes) d'une part et à des érythrocytes d'autre part. Ils provoquent une agrégation d'érythrocytes en présence de ladite substance spécifique dans une quantité cliniquement significative permettant la détection et/ou la quantification de ladite substance spécifiée dans le sang, le plasma, le sérum ou d'autres liquides corporels. L'invention concerne également l'utilisation de compositions comprenant des mélanges de conjugués ou d'hybrides d'anticorps réactifs aux différents déterminants antigéniques, sur des érythrocytes et/ou différents déterminants antigéniques se trouvant sur ladite substance spécifique, afin d'augmenter la sensibilité des compositions pour détecter et/ou quantifier ladite substance spécifique dans le sang, le plasma, le sérum ou d'autres liquides corporels. L'invention concerne en outre l'utilisation de telles compositions dans des combinaisons avec des anticorps réactifs auxdites substances spécifiques, mais pas aux érythrocytes, afin d'ajuster la sensibilité de la détection et/ou de la quantification de ladite substance antigénique spécifiée dans le sang, le plasma, le sérum ou d'autres liquides corporels. De tels anticorps, conjugués et/ou hybrides peuvent être d'origine monoclonale ou polyclonale. On peut employer cette invention en médecine vétérinaire et humaine à des fins de diagnostic.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB888804933A GB8804933D0 (en) | 1988-03-02 | 1988-03-02 | Compositions for simple detection &/quantification of acute phase proteins in body liquids |
GB8804933 | 1988-03-02 | ||
GB8903820A GB2218100A (en) | 1988-03-02 | 1989-02-20 | Conjugates for the detection and/or quantification of antigenic substances in body fluids |
GB8903820.2 | 1989-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989008261A1 true WO1989008261A1 (fr) | 1989-09-08 |
Family
ID=26293567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NO1989/000021 WO1989008261A1 (fr) | 1988-03-02 | 1989-03-01 | Composition de detection et/ou de quantification simple de substances antigeniques dans des liquides corporels |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3190389A (fr) |
GB (1) | GB2218100A (fr) |
WO (1) | WO1989008261A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0602290A1 (fr) * | 1992-12-04 | 1994-06-22 | Philippe Pouletty | Médicaments cellulaires à ancres |
EP0431171B1 (fr) * | 1989-04-25 | 1995-06-21 | Iatron Laboratories, Inc. | Anticorps monoclonal contre proteine c-reactive |
US5500345A (en) * | 1989-04-25 | 1996-03-19 | Iatron Laboratories, Inc. | Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein |
EP1739430A3 (fr) * | 2002-12-20 | 2007-01-17 | Axis-Shield Asa | Analyse CVD |
CN105929173A (zh) * | 2016-04-27 | 2016-09-07 | 深圳市国赛生物技术有限公司 | 一种血清淀粉样蛋白a的检测试剂盒及检测方法 |
CN106198993A (zh) * | 2016-06-22 | 2016-12-07 | 浙江达美生物技术有限公司 | 一种降钙素原蛋白的测定试剂及其制备方法 |
CN106290907A (zh) * | 2016-08-03 | 2017-01-04 | 宁波普瑞柏生物技术有限公司 | 全血中血清淀粉样蛋白a定量检测试剂以及检测方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
DE4202923A1 (de) * | 1992-02-01 | 1993-08-05 | Behringwerke Ag | Verfahren zur bestimmung von antigenen oder antikoerpern in gegenwart eines immunkomplexes |
US5474893A (en) * | 1994-04-11 | 1995-12-12 | Fang; Ta-Yun | Spectrophotometry of amyloid degrading activity in serum or tissue |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2167086A (en) * | 1982-04-12 | 1986-05-21 | Hybritech Inc | Antibodies having dual specificities, their preparation and uses therefor |
-
1989
- 1989-02-20 GB GB8903820A patent/GB2218100A/en not_active Withdrawn
- 1989-03-01 AU AU31903/89A patent/AU3190389A/en not_active Abandoned
- 1989-03-01 WO PCT/NO1989/000021 patent/WO1989008261A1/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2167086A (en) * | 1982-04-12 | 1986-05-21 | Hybritech Inc | Antibodies having dual specificities, their preparation and uses therefor |
Non-Patent Citations (6)
Title |
---|
MEDLINE (NLM Database), Accession number 05223293; Sabouraudia 1984, 22 (1), p. 73-7, (DE CAMARGO Z.P. et al.): "Titration of antibodies to Paracocoidioides brasiliensis by erythro-immunoassay (EIA)". * |
MEDLINE (NLM Database), Accession number 05505845; Biomed Biochem Acta 1984, 43 (10), p. 1191-8, (PORSTMANN T. et al.): "Application of antibody chimera in enzyme and erythro immunoassay". * |
MEDLINE (NLM Database), Accession number 05946792; Eur. J. Immunol, Jun 1986, 16 (6), p. 679-83 (LANSDORP P.M. et al.): "Cyclic tetramolecular complexes of monoclonal antibodies: a new type of crosslinking reagent". * |
MEDLINE (NLM Database), Accession number 06193671; J. Immunol Methods Apr. 2 1987; 98 (1), p. 83-9, (GERMANI Y. et al.): "Antibody chimera technique applied to the detection of Escherichia". * |
PATENT ABSTRACTS OF JAPAN, Vol. 8, No. 141, (P-283), & JP,A,59 040 166, (05-03-1984). * |
PROC. NATL. ACAD. SCI. USA, Vol. 83, October 1986, p. 7989-7993, (M.R. SURESH et al.): "Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays", see in particular pages 7992-93. * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0431171B1 (fr) * | 1989-04-25 | 1995-06-21 | Iatron Laboratories, Inc. | Anticorps monoclonal contre proteine c-reactive |
US5500345A (en) * | 1989-04-25 | 1996-03-19 | Iatron Laboratories, Inc. | Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein |
EP0602290A1 (fr) * | 1992-12-04 | 1994-06-22 | Philippe Pouletty | Médicaments cellulaires à ancres |
EP1739430A3 (fr) * | 2002-12-20 | 2007-01-17 | Axis-Shield Asa | Analyse CVD |
EP1573335B1 (fr) * | 2002-12-20 | 2007-12-05 | Axis-Shield Asa | Dosage permettant d'indiquer un risque de maladie cardiovasculaire |
US10101325B2 (en) | 2002-12-20 | 2018-10-16 | Sundrehagen, Erling, Dr. | Determination method for calprotectin and the use of calprotectin as a predictive marker for cardiovascular disease |
CN105929173A (zh) * | 2016-04-27 | 2016-09-07 | 深圳市国赛生物技术有限公司 | 一种血清淀粉样蛋白a的检测试剂盒及检测方法 |
CN106198993A (zh) * | 2016-06-22 | 2016-12-07 | 浙江达美生物技术有限公司 | 一种降钙素原蛋白的测定试剂及其制备方法 |
CN106290907A (zh) * | 2016-08-03 | 2017-01-04 | 宁波普瑞柏生物技术有限公司 | 全血中血清淀粉样蛋白a定量检测试剂以及检测方法 |
CN106290907B (zh) * | 2016-08-03 | 2018-07-06 | 宁波普瑞柏生物技术股份有限公司 | 全血中血清淀粉样蛋白a定量检测试剂以及检测方法 |
Also Published As
Publication number | Publication date |
---|---|
GB2218100A (en) | 1989-11-08 |
AU3190389A (en) | 1989-09-22 |
GB8903820D0 (en) | 1989-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2901296B2 (ja) | カンピロバクター・ピロリの高分子型細胞関連蛋白の調製法とカンピロバクター・ピロリ感染の血清学的検出のための用法 | |
KR0148619B1 (ko) | Pivka-x의 측정방법 및 측정시약 | |
DE69028513T2 (de) | Träger zur bindung von antiphospholipid-antikörpern, diese antikörper verwendender immunotest und kit dafür | |
KR20130032869A (ko) | 신규 단클론항체 및 d 다이머의 면역학적 측정법 | |
AU654497B2 (en) | Analyte variant analysis | |
US20130143243A1 (en) | Reagent and reagent kit for measurement of fdp, and measurement method | |
WO2002079782A1 (fr) | Reactif et procede pour l'immunoanalyse de l'elastase 1, et procede de detection de pathologie pancreatique | |
WO1989008261A1 (fr) | Composition de detection et/ou de quantification simple de substances antigeniques dans des liquides corporels | |
JPH03229153A (ja) | リュウマチ病の診断に有用な特異的抗体または抗原の存在を検出する方法およびそれに用いられるテストキット | |
EP0968429B1 (fr) | Methode et necessaire correspondant permettant de determiner le phenotype d'une haptoglobine et applications de celle-ci | |
Wu et al. | Highly sensitive method for the assay of plasminogen | |
JPH0580053A (ja) | ヒト子宮体癌細胞の免疫化学的検出方法 | |
EP0354954B1 (fr) | Reactif et procede servant a detecter le facteur rhumatoide | |
GB2217335A (en) | Compositions for isolation and immobilisation of C-reactive protein in body liquids | |
RU2210074C2 (ru) | Иммунологический анализ человеческого медуллазина и диагностика рассеянного склероза с его помощью | |
JPH05507095A (ja) | 子宮内膜抗原、組成物、試験キット及び子宮内膜抗体検出方法 | |
Sato et al. | Treponema pallidum specific IgM haemagglutination test for serodiagnosis of syphilis. | |
JP2878317B2 (ja) | ラミニン測定試薬 | |
GB2217840A (en) | Compositions for detection and/or quantification of an isolated acute phase protein in body liquids | |
JPH08193999A (ja) | 免疫測定法 | |
Ballou et al. | Absence of a binding reactivity of human C-reactive protein for immunoglobulin or immune complexes | |
JP4363767B2 (ja) | 多発性硬化症の検査方法 | |
JP2001305141A (ja) | ヒトメダラシンの免疫学的測定方法 | |
NO153987B (no) | Fremgagsmaate for bestemmelse av celletype eller forenlighet paa en fast matrise. | |
Migliorini et al. | The serum capacity to solubilize immune complexes (ICSC) measured by an enzyme-anti-enzyme complex probe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI HU JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |